Dablap Pharmaceuticals Private Limited
About Dablap Pharmaceuticals Private Limited
Data last updated:
Dablap Pharmaceuticals Private Limited is a private limited company based in Delhi, India. It operates in the manufacturing segment of the chemicals sector. It was incorporated on 05 February 2019 and has been in existence for over 7 years.
The company is registered with the Registrar of Companies (ROC), Delhi, under CIN U24200DL2019PTC345511. Its GSTIN is 07AAHCD0833C1Z5 (Delhi).
The company has an authorised share capital of ₹10 Lakh and a paid-up capital of ₹2 Lakh. It is led by directors Sanjay and Priyanka Trivedi.
Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at B – 297 GF Kh No. 36/1/1 Gali No – 9 Ph – 10 Shiv Vihar Karawal Nagar, Delhi, India – 110094.
As per the financials filed for FY 2025, the company reported a revenue of ₹19.07 Lakh, a growth of 38% compared to the previous year. For the same year it recorded a net loss of ₹9,753 (net margin -0.5%) and EBITDA of -₹9,549 (EBITDA margin -0.5%). Revenue has grown at a compounded annual rate (CAGR) of 4% over three years and 18% over five years.
The current compliance status is marked as compliant by the Registrar of Companies.
- EmailLocked
- TelephoneLocked
- WebsiteLocked
- Social MediaLocked
- Registered AddressB – 297 GF Kh No. 36/1/1 Gali No – 9 Ph – 10 Shiv Vihar Karawal Nagar, Delhi, India – 110094
- IndustryChemicals, Manufacturing, Other Chemical Product
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
- One PDF report, delivered after checkout
Business Activity of Dablap Pharmaceuticals Private Limited
The main business activity of Dablap Pharmaceuticals is trade. In detail, this covers wholesale trading.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| G | Trade | G1 | Wholesale Trading | Locked |
Business activity turnover details
Turnover share and past changes in activity are in the company report.
- Turnover contribution
- Historical classifications
- Filing-level activity changes
Verified entity values are shown only after access is granted.
Financials of Dablap Pharmaceuticals Private Limited FY 2025 filings available
Dablap Pharmaceuticals Private Limited reported revenue of ₹19.07 Lakh (up 38% YoY) for FY 2025.
Compounded Annual Growth Rate (CAGR) of Dablap Pharmaceuticals Private Limited
Revenue has grown at a compounded annual rate (CAGR) of 18% over five years, including 38% growth in the latest year. EBITDA rose 22% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary of Dablap Pharmaceuticals Private Limited
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | •••• | •••• | •••• | •••• | •••• |
| Other Income | •••• | •••• | •••• | •••• | •••• |
| Total Revenue | •••• | •••• | •••• | •••• | •••• |
| Cost of Materials Consumed | •••• | •••• | •••• | •••• | •••• |
| Employee Benefit Expense | •••• | •••• | •••• | •••• | •••• |
| Finance Costs | •••• | •••• | •••• | •••• | •••• |
| Depreciation and Amortisation | •••• | •••• | •••• | •••• | •••• |
| Other Expenses | •••• | •••• | •••• | •••• | •••• |
| Total Expenses | •••• | •••• | •••• | •••• | •••• |
| EBITDA | -₹9,549 | •••• | •••• | •••• | •••• |
| Profit Before Tax | •••• | •••• | •••• | •••• | •••• |
| Tax Expense | •••• | •••• | •••• | •••• | •••• |
| Net Profit (PAT) | -₹9,753 | •••• | •••• | •••• | •••• |
| Balance Sheet | |||||
| Share Capital | •••• | •••• | •••• | •••• | •••• |
| Reserves and Surplus | •••• | •••• | •••• | •••• | •••• |
| Net Worth (Total Equity) | •••• | •••• | •••• | •••• | •••• |
| Long-term Borrowings | •••• | •••• | •••• | •••• | •••• |
| Short-term Borrowings | •••• | •••• | •••• | •••• | •••• |
| Trade Payables | •••• | •••• | •••• | •••• | •••• |
| Total Liabilities | •••• | •••• | •••• | •••• | •••• |
| Fixed Assets | •••• | •••• | •••• | •••• | •••• |
| Investments | •••• | •••• | •••• | •••• | •••• |
| Inventories | •••• | •••• | •••• | •••• | •••• |
| Trade Receivables | •••• | •••• | •••• | •••• | •••• |
| Cash and Bank Balance | •••• | •••• | •••• | •••• | •••• |
| Total Assets | •••• | •••• | •••• | •••• | •••• |
Financial Ratios of Dablap Pharmaceuticals Private Limited
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | -0.5% | •••• | •••• | •••• | •••• |
| Net Profit Margin | -0.5% | •••• | •••• | •••• | •••• |
| Return on Equity (ROE) | •••• | •••• | •••• | •••• | •••• |
| Return on Capital Employed (ROCE) | •••• | •••• | •••• | •••• | •••• |
| Return on Assets (ROA) | •••• | •••• | •••• | •••• | •••• |
| Liquidity and Debt | |||||
| Current Ratio | •••• | •••• | •••• | •••• | •••• |
| Quick Ratio | •••• | •••• | •••• | •••• | •••• |
| Debt-to-Equity Ratio | •••• | •••• | •••• | •••• | •••• |
| Interest Coverage Ratio | •••• | •••• | •••• | •••• | •••• |
| Efficiency and Growth | |||||
| Asset Turnover | •••• | •••• | •••• | •••• | •••• |
| Receivable Days | •••• | •••• | •••• | •••• | •••• |
| Payable Days | •••• | •••• | •••• | •••• | •••• |
| Inventory Days | •••• | •••• | •••• | •••• | •••• |
| Revenue Growth | •••• | •••• | •••• | •••• | •••• |
| Net Profit Growth | •••• | •••• | •••• | •••• | •••• |
Paid data: the figures shown as dots are available after purchase of the company report. Figures as filed with the MCA in Form AOC-4. The full year-wise statements and ratios of Dablap Pharmaceuticals are in the company report.
Financial statements from FY 2019
Earlier years and trend charts are in the company report.
- Income statements
- Balance sheets
- Cash-flow statements
- Ratios and benchmarks
Verified entity values are shown only after access is granted.
Peer Comparison of Dablap Pharmaceuticals Private Limited
Dablap Pharmaceuticals Private Limited is compared with the companies closest to it by revenue in the Pharma industry (Pharmaceuticals). Net profit, margin and employee counts of each company are in the company report.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Nityon Pharmaceuticals (OPC) Private Limited | ₹19.13 Lakh (FY 2024) | •••• | •••• | 263.0% | •••• | Tq-Sindkhedraja, Buldhana, Maharashtra, India |
| Aaravya Pharmaceuticals Private Limited | ₹19.12 Lakh (FY 2025) | •••• | •••• | 1619.0% | •••• | Muzaffarpur, Bihar, India |
| Ado Pharmaceuticals Private Limited | ₹19.12 Lakh (FY 2024) | •••• | •••• | 47.0% | •••• | Mohali, Punjab, India |
| Orixx Pharmaceuticals Private Limited | ₹19.1 Lakh (FY 2020) | •••• | •••• | •••• | Bareilly, Uttar Pradesh, India | |
| Arvikha Pharmaceuticals Private Limited | ₹19.09 Lakh (FY 2025) | •••• | •••• | 15.0% | •••• | Kolkata, West Bengal, India |
| Dablap Pharmaceuticals Private Limited this company | ₹19.07 Lakh (FY 2025) | •••• | •••• | 38.0% | •••• | Delhi, India |
| Eligens Pharmaceuticals Private Limited | ₹19.06 Lakh (FY 2025) | •••• | •••• | 29.0% | •••• | Lucknow, Uttar Pradesh, India |
| Pinakin Pharmaceuticals Private Limited | ₹19.03 Lakh (FY 2024) | •••• | •••• | 3.0% | •••• | Vadodara, Gujarat, India |
| Mazing Pharmaceuticals (OPC) Private Limited | ₹19.01 Lakh (FY 2025) | •••• | •••• | 492.0% | •••• | Indore, Madhya Pradesh, India |
| Karthikeya Drugs & Pharmaceuticals Private Limited | ₹19 Lakh (FY 2019) | •••• | •••• | -12.0% | •••• | Hyderabad, Telangana, India |
| Megrez Pharmaceuticals & Chemicals Private Limited | ₹19 Lakh (FY 2025) | •••• | •••• | 1.0% | •••• | Noida, Uttar Pradesh, India |
Peers are the five companies nearest above and the five nearest below Dablap Pharmaceuticals by revenue in the Pharma industry (Pharmaceuticals), from the latest filed financials of each company. Net profit, margin and employee counts of each peer are in the company report.
Board of Directors of Dablap Pharmaceuticals Private Limited
Dablap Pharmaceuticals has 2 directors on record. No former directors are listed.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Sanjay | Director | 05 Feb 2019 | 7 Years 8 Months | Current |
| Priyanka Trivedi | Director | 05 Feb 2019 | 7 Years 8 Months | Current |
Ownership and Shareholding of Dablap Pharmaceuticals Private Limited
Shareholding and ownership data
Promoter, institutional, public and beneficial ownership figures are in the company report.
- Ownership categories
- Historical changes
- Group structure
- FII and DII holdings
Verified entity values are shown only after access is granted.
Charges & Borrowings of Dablap Pharmaceuticals Private Limited
Dablap Pharmaceuticals Private Limited does not have any charges (loans) registered with the Registrar of Companies.
Employees and EPFO Compliance at Dablap Pharmaceuticals Private Limited
Employment history and EPFO contributions of people linked to Dablap Pharmaceuticals.
Employee and EPFO history
Monthly headcount, contribution history and filing status are in the company report.
- Monthly headcount
- PF contributions
- ECR filing status
- Establishment history
Verified entity values are shown only after access is granted.
Recent Activity on Dablap Pharmaceuticals Private Limited
Dablap Pharmaceuticals Private Limited has 2 board changes on record since 2019: 2 appointments. The latest: Priyanka Trivedi was appointed as Director on 05 Feb 2019.
Credit Ratings, Litigation & Regulatory Alerts for Dablap Pharmaceuticals Private Limited
Credit ratings, litigation, and regulatory alerts
Credit ratings, court records and regulatory alerts are in the company report.
- Rating history
- Court and tribunal cases
- Regulatory alerts
- Director-linked violations
Verified entity values are shown only after access is granted.
MSME Payment Delays by Dablap Pharmaceuticals Private Limited
MSME payment history
Amounts due to small suppliers, the reasons given and MSME-1 filings are in the company report.
- Outstanding amounts
- Delay periods and reasons
- MSME-1 filing history
- Vendor payment signals
Verified entity values are shown only after access is granted.
Subsidiaries & Group Companies of Dablap Pharmaceuticals Private Limited
Corporate group structure
Parent, subsidiary, associate and joint venture records with holdings are in the company report.
- Parent company
- Subsidiaries and ownership
- Associates and joint ventures
- Entity investments
Verified entity values are shown only after access is granted.
GST Compliance of Dablap Pharmaceuticals Private Limited
Dablap Pharmaceuticals has 1 GST registration: 1 active.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 07AAHCD0833C1Z5 | Delhi | Active | 12 Feb 2019 |
GST registrations and filing compliance
State-wise GST registrations, return filing status and HSN or SAC codes are in the company report.
- GSTIN registrations
- State-wise filing status
- HSN and SAC details
- Tax jurisdiction records
Verified entity values are shown only after access is granted.
MCA Filings & Documents of Dablap Pharmaceuticals Private Limited
MCA filings and documents
Filed forms, annual returns, financial statements and charge filings with their dates are in the company report.
- Incorporation documents
- Annual returns and statements
- Charge filings
- Complete filing index
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Dablap Pharmaceuticals Private Limited
Dablap Pharmaceuticals is an active private limited company based in Delhi, India. The company works in manufacturing, within the chemicals industry. It was incorporated on 05 February 2019 (7+ years old) and is registered under CIN U24200DL2019PTC345511.
Dablap Pharmaceuticals reported revenue of ₹19.07 Lakh for FY 2025 (up 38% YoY).
Dablap Pharmaceuticals has 2 current directors:
- Sanjay - Director
- Priyanka Trivedi - Director
Dablap Pharmaceuticals reported a net loss of ₹9,753 (net margin -0.5%) and EBITDA of -₹9,549 (EBITDA margin -0.5%) for FY 2025, as per its filed financial statements.
The compounded annual growth rate (CAGR) of the revenue of Dablap Pharmaceuticals is 4% over three years and 18% over five years. In the latest year (FY 2025) revenue rose 38%. CAGR is the steady yearly rate that links the first and the last year.
The GSTIN of Dablap Pharmaceuticals is 07AAHCD0833C1Z5, registered in Delhi.
The CIN (Corporate Identification Number) of Dablap Pharmaceuticals is U24200DL2019PTC345511. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Dablap Pharmaceuticals was incorporated on 05 February 2019, making it 7+ years old. It is registered with the Registrar of Companies, Delhi.
The peers of Dablap Pharmaceuticals by revenue are Nityon Pharmaceuticals (OPC) Private Limited, Aaravya Pharmaceuticals Private Limited, Ado Pharmaceuticals Private Limited, Orixx Pharmaceuticals Private Limited, Arvikha Pharmaceuticals Private Limited and 5 more, all in the Pharma industry (Pharmaceuticals).
Priyanka Trivedi was appointed as Director on 05 Feb 2019. Sanjay was appointed as Director on 05 Feb 2019.
The registered office of Dablap Pharmaceuticals is at B – 297 GF Kh No. 3611 Gali No – 9 Ph – 10 Shiv Vihar Karawal Nagar, Delhi, India – 110094.